Drug intelligence / Profile preview

STUP-002

Development stage: Preclinical
Lead developer: Stand Up Therapeutics
Modality: Gene Therapies
Administration: Intrathecal

Overview

STUP-002 is an AAV9-based in vivo gene therapy being developed by Stand Up Therapeutics for the treatment of Parkinson's disease. The therapy utilizes a direct lineage reprogramming approach to convert endogenous astrocytes into functional dopaminergic neurons within the brain. By replenishing the lost dopaminergic neuronal population, STUP-002 aims to restore motor function and address the underlying pathology of the disease. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on STUP-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STUP-002.

Explore the full profile